Among patients with HCV genotype @ infection , an SVR@ was achieved by @ % , @ % , and @ % of those in the daclatasvir @-week group , the daclatasvir @-week group , or the placebo group , respectively ; among patients with HCV genotype @ infection , an SVR@ was achieved by @ % , @ % , and @ % of patients in these groups , respectively .